Tune Therapeutics

Company profile

About Tune Therapeutics

Tune Therapeutics is a biotechnology company pioneering a new class of genetic medicine through epigenetic editing. Founded on cutting-edge advances in gene regulation mechanics, Tune has developed TEMPO, a proprietary platform that enables precise control over gene activity without cutting or permanently altering DNA sequences. Unlike traditional gene editing approaches that create irreversible deletions or knockouts, TEMPO can dial gene expression up or down in a graded, tunable, and reversible manner—from zero to up to 10,000x normal expression levels. The company's technology addresses a fundamental limitation in genetic medicine: the ability to treat not just rare single-gene disorders, but common, chronic, and age-related diseases that affect millions globally. TEMPO's modular design combines customizable DNA-binding domains (using modified Cas, ZFP, or TALE systems that cannot cut DNA) with effector proteins that alter epigenetic marks and chromatin accessibility. This approach allows Tune to target master controllers of cellular identity, steer stem cells toward specific pathways, replace cells lost to aging, repair age-damaged tissues, reduce chronic inflammation, and reverse gene dysregulation patterns underlying chronic diseases. Based in Durham, North Carolina and Seattle, Washington, Tune Therapeutics was founded by a veteran leadership team with deep expertise in gene and cell therapy, genome editing, and epigenetics. The company's lead program, Tune-401, is a first-in-class epigenetic silencer for Hepatitis B currently in Phase 1b/2a clinical trials. With its powerful multiplex capacity and integrated discovery-to-development process, Tune aims to bring gene, cell, and regenerative therapies into a new era—addressing the common and chronic diseases straining healthcare systems and limiting human healthspan on a global scale.

Company description · Tune Therapeutics official website